Shearman & Sterling represented BofA Merrill Lynch and Morgan Stanley as joint book-running managers and representatives of the several underwriters in connection with Amgen’s registered offering of $6 billion of senior notes, consisting of $1 billion of 1.875% Senior Notes due 2014, $1 billion of 2.50% Senior Notes due 2016, $1.75 billion of 3.875% Senior Notes due 2021 and $2.25 billion of 5.15% Senior Notes due 2041. Amgen is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.

The following Shearman & Sterling team advised the underwriters in the transaction: partners John Wilson (San Francisco-Capital Markets), Lisa Jacobs (New York-Capital Markets), James Donato (San Francisco-Litigation) and Tina Patel (Palo Alto-Intellectual Property Transactions); counsel Jung-Kyu McCann (Palo Alto-Capital Markets); and associates Phillip Monk (Palo Alto-Capital Markets), Nathan Mee (San Francisco-Capital Markets), Zheng Bao (Palo Alto-Intellectual Property Transactions), Anil Kalia (Palo Alto-Tax), Eric Naftel (Palo Alto-Tax) and Emily Griffen (San Francisco-Litigation).